Cart
sales@molnova.com
Bredinin aglycone
CAS No. 56973-26-3
Bredinin aglycone( 5-Hydroxy-1H-imidazole-4-carboxamide )
Catalog No. M24560 CAS No. 56973-26-3
Bredinin aglycone is a purine nucleotide analog. It can be used to examine the efficiency of catalysts for the preparation of purine nucleotide analogs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 29 | In Stock |
|
| 10MG | 37 | In Stock |
|
| 25MG | 76 | In Stock |
|
| 50MG | 129 | In Stock |
|
| 100MG | 184 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 477 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBredinin aglycone
-
NoteResearch use only, not for human use.
-
Brief DescriptionBredinin aglycone is a purine nucleotide analog. It can be used to examine the efficiency of catalysts for the preparation of purine nucleotide analogs.
-
DescriptionBredinin aglycone is a purine nucleotide analog. It can be used to examine the efficiency of catalysts for the preparation of purine nucleotide analogs.
-
In Vitro——
-
In Vivo——
-
Synonyms5-Hydroxy-1H-imidazole-4-carboxamide
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number56973-26-3
-
Formula Weight127.1
-
Molecular FormulaC4H5N3O2
-
Purity>98% (HPLC)
-
SolubilityH2O: 1 mg/mL (7.87 mM; Need ultrasonic)
-
SMILESNC(c(nc[nH]1)c1O)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Scism RA, et al. Synthesis of nucleotide analogues by a promiscuous phosphoribosyltransferase. Org Lett. 2007 Oct 11;9(21):4179-82. Epub 2007 Sep 14.
molnova catalog
related products
-
Amyloid β-Protein (3...
β Amyloid (3-40) is aAβ Fragment.
-
2"-O-β-L-Galorientin
2"-O-β-L-Galorientin is a natual product isaolated from?Trollius chinensis Bunge.
-
LY-3475070
LY-3475070 is a potent and selective CD73 inhibitor with an IC50 of 28 nM, and its use alone or in combination with pembrolizumab is currently being tested in patients with advanced cancer.
